Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- cisplatin
- Demadex IV (torsemide)
Interactions between your drugs
CISplatin torsemide
Applies to: cisplatin, Demadex IV (torsemide)
GENERALLY AVOID: The concomitant use of loop diuretics with cisplatin may increase the risk of ototoxicity. Loop diuretics, especially ethacrynic acid and high doses of furosemide, and cisplatin have been individually associated with ototoxicity.
MANAGEMENT: This combination should be avoided unless the potential benefit outweighs the risk. Audiometric testing is recommended if these drugs are given concurrently. Patients should be advised to promptly notify their physician if they experience hearing loss or tinnitus.
References (6)
- Komune S, Snow JB (1981) "Potentiating effects of cisplatin and ethacrynic acid in ototoxicity." Arch Otolaryngol, 107, p. 594-7
- Rhodes T, Twentyman PR (1992) "A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines." Br J Cancer, 65, p. 684-90
- (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
- Brock PR, Knight KR, Freyer DR, et al. (2012) "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale." J Clin Oncol, 30, p. 2408-17
- Parsons SK, Neault MW, Lehmann, et al. (1998) "Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma." Bone Marrow Transplant, 22, p. 669-74
- Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O (2013) "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci, 34, p. 458-69
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Loqtorzi
Loqtorzi (toripalimab-tpzi) is a PD-1 inhibitor medicine used for the treatment of advanced ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.